- Home
- / Genomic Valley Biotech
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Genomic Valley Biotech financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
₹1.7 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 16, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| INR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.9M | 9.9M | 8.5M | 2.1M | 705.0K | 27.2M | 1.7M |
| Cost of goods sold | 453.0K | 472.0K | (677.0K) | 816.0K | 19.0K | 15.8M | |
| Gross profit | 5.5M | 9.4M | 9.3M | 1.3M | 686.0K | 11.4M | 1.7M |
| Gross profit margin, % | 92.4% | 95.2% | 109.4% | 60.8% | 97.3% | 41.8% | 100.9% |
| Operating expense total | 4.5M | 5.2M | 3.5M | 2.6M | 4.5M | 2.6M | 1.5M |
| Depreciation and amortization | 757.0K | 1.9M | 1.9M | 1.9M | 844.0K | 79.0K | 11.0K |
| EBITDA | 1.0M | 4.3M | 5.7M | (1.3M) | (3.7M) | 8.8M | 168.0K |
| EBITDA margin, % | 17.0% | 43.6% | 67.7% | -64.2% | -527.4% | 32.4% | 10.2% |
| EBIT | 466.0K | 2.4M | 3.8M | (3.2M) | (370.0K) | 6.1M | 157.0K |
| EBIT margin, % | 7.8% | 23.9% | 45.4% | -155.1% | -52.5% | 22.4% | 9.5% |
| Interest income | 124.0K | 9.0K | 22.0K | 784.0K | 426.0K | ||
| Interest expense | 4.0K | 16.0K | 1.8M | 1.8M | 430.0K | 27.0K | 6.0K |
| Pre tax profit | 586.0K | 2.3M | 2.1M | (5.0M) | (16.0K) | 6.5M | 151.0K |
| Income tax expense | 245.0K | 22.0K | (803.0K) | 572.0K | 77.0K | 6.0K | |
| Net Income | 341.0K | 2.3M | 2.9M | (5.6M) | (93.0K) | 6.5M | 151.0K |